China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 21Aug 26Aug 31Sep 3Sep 8Sep 11Sep 16Sep 21

Key dataSep 21, 2026

OpenCNY 14.43

From 52W high−45.22%

Volume6.20M

Market capCNY 7.28B

P/E (TTM)64.6x

P/S (TTM)3.9x

Div yield1.55%

Key dataSep 21, 2026

Open

CNY 14.43

From 52W high

−45.22%

Volume

6.20M

Market cap

CNY 7.28B

ValuationView details →

P/E (Fwd)

20.9x

EV/EBITDA

24.2x

P/E (TTM)

64.6x

RSI (14)

45.7

MomentumView details →

1D Return

−4.94%

YTD Return

−36.28%

ValuationView details →

P/E (Fwd)

20.9x

P/E (TTM)

64.6x

EV/EBITDA

24.2x

EV/Sales

3.5x

P/S (TTM)

3.9x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

48.13%

Net Margin

0.19%

EBITDA Margin

14.59%

ROE (TTM)

0.05%

ROA (TTM)

0.04%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

+1.21%

EPS YoY

−98.03%

FCF YoY

—

Revenue CAGR 3Y

−9.29%

EPS CAGR 3Y

−36.52%

EBITDA YoY

—

MomentumView details →

1D Return

−4.94%

YTD Return

−36.28%

1Y Return

−42.47%

RSI (14)

45.7

vs 50D SMA

−4.48%

vs 200D SMA

−22.54%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.32x

Quick Ratio

5.00x

Div Yield

1.55%

Div Rate

CNY 0.22

Div Growth 1Y

−32.61%

EarningsView details →

EPS (Actual)

CNY 0.04

EPS Surprise

−89.23%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.05

Avg Surprise (4Q)

−89.23%

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

1.84B

Net Income (TTM)

3.44M

Op. CF (TTM)

−23.95M

Next earningsOct 22, 2026 →

Latest newsMore news →

Boyaa Bio-Pharmaceutical announced its first-half 2026 results: revenue of 644 million yuan, down 36.14% year-on-year; net profit attributable to shareholders of 51.19 million yuan, down 77.28% year-on-year.31d ago

Boyaa Bio's controlled subsidiary Dalateqi Boyaa Plasma Collection Co., Ltd. obtained a plasma collection license from the Health Commission of Inner Mongolia Autonomous Region, valid from July 17, 2026 to July 16, 2028.46d ago

Similar companies

凯盛新材301069.SZ 中原内配002448.SZ 恒星科技002132.SZ 海特高新002023.SZ 爱迪特301580.SZ 新时达002527.SZ Find similar companies →

Latest newsMore news →

Boyaa Bio-Pharmaceutical announced its first-half 2026 results: revenue of 644 million yuan, down 36.14% year-on-year; net profit attributable to shareholders of 51.19 million yuan, down 77.28% year-on-year.31d ago Boyaa Bio's controlled subsidiary Dalateqi Boyaa Plasma Collection Co., Ltd. obtained a plasma collection license from the Health Commission of Inner Mongolia Autonomous Region, valid from July 17, 2026 to July 16, 2028.46d ago